



## **Ventripoint Diagnostics Ltd.**

**Symbol:** TSX.V: VPT

**Market Cap:** 28.8M

**Sector:** Technology

**Purpose:** Raise Awareness / Open Market Buying

## **About Ventripoint Diagnostics Ltd.**

Ventripoint has become an industry leader in the application of AI (Artificial Intelligence) to echocardiography. Ventripoint's VMS products are powered by its proprietary KBR technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI. This affordable, gold-standard alternative allows cardiologists greater confidence in the management of their patients. Providing better care to patients serves as a springboard and basic standard for all of Ventripoint's products that guide our future developments. In addition, VMS+ is versatile and can be used with all ultrasound systems from any vendor supported by regulatory market approvals in the U.S., Europe and Canada.

## **Investor Bullet Points:**

- AI imaging company with proprietary and unique whole-heart analysis technology
- Products are approved in USA (FDA), Europe (CE Mark), Canada (HC) and China (FDA)
- 11 top hospitals installed and entering high growth phase with goal to have 80-100 users by mid-2022

## **Dr. George Adams, President & CEO**

Dr. Adams is known as a scientist, innovator, entrepreneur and venture financier. Using his medical and engineering knowledge he has spent 40 years developing and commercializing medical discoveries related to the heart and blood vessels. The products which he has commercialized have been implanted or **used to support life in 300 million people in the last 35 years**. Dr Adams was named a Technology Pioneer by the World Economic Forum, attended the Davos meeting and was featured in Time magazine worldwide. Ventripoint is his seventh business. Previous companies were bought by Pfizer, Dupont, Afilias or remain publicly traded.